On the 12 month timeframe, or yearly supercycle, ILMN seems to be consolidating enough these first 3 months into 2024 to ultimately flip to the upside with maximum bull force. The company has a solid catalyst with AI facilitating the end goal of a super biopharma product that perhaps all humanity may have to rely on: a panacea. This panacea may come in the form of a machine that prompts the users exactly what symptoms they have, and produce a medicine that cures said symptoms. Something very well regulated and sophisticated enough to fuel the bull run of the decade for ILMN. A merger should be the cherry on top, and maybe the BNGO merger prophecy comes to fruition, but this only time will tell.